Prostate Cancer Imaging
Curasight A/S is active in uPAR PET imaging research for untreated, localised prostate cancer, with interest in diagnostic performance and lesion characterisation in clinically defined disease.
- PSMA-independent molecular imaging
- uPAR PET signal assessment
- Gleason grade and ISUP grade discrimination
The sponsor’s work in this area centres on improving tumour detection and supporting more precise risk stratification in early-stage prostate cancer.
Glioblastoma Targeted Therapy
The company also funds research in glioblastoma involving uPAR-targeted radioligand therapy, reflecting a therapeutic focus on aggressive central nervous system tumours.
- Targeted radioligand therapy
- uPAR-directed oncology
- Brain tumour treatment research
This area of interest aligns with efforts to advance precision oncology approaches for difficult-to-treat high-grade glioma.
Diagnostic Oncology
Curasight A/S maintains a strong focus on oncologic imaging biomarkers and the clinical utility of PET-based diagnostics in cancer evaluation.
- Biomarker-driven imaging
- Diagnostic accuracy
- Tumour classification
Its research portfolio shows particular interest in distinguishing clinically relevant disease subgroups using molecular imaging.
